CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study

Inclusion Criteria: * Healthy infant born at ≥37 weeks' gestation * Age 2 months (+ up to 14 days) at time of first study visit * Parent/guardian or legally authorized representative has given informed consent for their child's participation. Exclusion Criteria: * Already received any routine 2-month immunizations * Previous laboratory confirmed pneumococcal disease * Previous receipt of any pneumococcal vaccine * Confirmed or suspected immunodeficiency, including but not limited to: * Congenital or acquired asplenia, or splenic dysfunction * B-cell (humoral), T-cell mediated, complement, or phagocytic function deficiency * HIV infection * Hematopoietic stem cell transplant (recipient) * Malignant neoplasms, including leukemia and lymphoma * Nephrotic syndrome * Solid organ or islet transplant (candidate or recipient) * A family history of congenital or hereditary immunodeficiency * Use of systemic immunosuppressive medication, including long-term corticosteroids, chemotherapy, radiation therapy, post-organ transplant therapy, intravenous immunoglobulin and/or specific monoclonal antibody therapy * Bleeding disorder or thrombocytopenia, that contraindicates intramuscular (IM) injection and/or blood collection or taking any anti-platelet or anti-coagulant medications * Any contraindication to vaccination as per the NACI Canadian Immunization Guide (https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html, accessed 16 September 2017). N…